Loading Events

Go Back

event image

Expert Forum on Multiple Myeloma – Dallas, TX

August 21 - 22, 2020

OVERVIEW

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Multiple Myeloma is a one-and-a-half-day meeting to discuss innovative, cutting edge ideas, tools and treatment strategies of MM in a think-tank style format. The meeting will bring together a select group of experts in the field of Multiple Myeloma for an open examination of new preclinical and translational data that will add to our knowledge and influence of practice over the coming years. The Expert Forum will have discussions on newly emerging preclinical and clinical data on sequencing in myeloma treatment, proteasome inhibition and cereblon modulation, and several new therapeutic targets. Additionally, the meeting will explore the use of CAR-T cells and their impact on treatment.

Event brochure is not yet available for this forum. 

KEY TOPICS

  • Review the current genomic landscape of multiple myeloma, clinical features of poor prognosis, mechanisms of resistance, immune signatures, and the integration of MRD into clinical trials
  • Examine the evolving role of transplantation and cellular therapy for the treatment of multiple myeloma, including CAR-T, ASCT, and allogeneic SCT
  • Evaluate key aspects of supportive care and complications, including bone disease, as well as definitions of disease, especially SMM/MGUS
  • Debate proteasome inhibitors, how to tailor treatment to patient populations, and broader strategies to overcome proteasome inhibitor resistance
  • Consider the benefits and challenges of long term lenalidomide therapy, as well as the emerging role of next generation IMiDs and Cell Mods
  • Discuss the integration of novel therapies and MoAbs in particular, including SLAMF7, CD 38, CAR-T cell therapy and targeting BCL2, as well as vaccines, and other novel targets, including nuclear export proteins and peptidase-avid alkylation
  • Understand the continued potential of targeting BCMA both in the setting of CAR-T therapy and MoAbs/ADC’s